logo
  

Svenska Handelsbanken To Sell Certain Operations In Finland

Svenska Handelsbanken AB (SVNLF.PK,SVNLY.PK), a Swedish lender, said on Wednesday that it has inked a deal with S-Bank Plc, Oma Savings Bank Plc, and Fennia Life Insurance Company Ltd, to sell certain of its operations in Finland.

The private customer, asset management, and investment services operations will be sold to S-Bank, who will also take over lease agreements for branch offices.

Oma Savings Bank will buy the small and medium-sized enterprise operations, whereas Fennia Life Insurance will acquire the life insurance operations.

The cash consideration of the deal is around 1.300 billion euros. In addition, it will obtain a maximum premium payment of 8.5 million euros. The transaction is expected to be finalized during second half of 2024.

The transaction includes lending volumes of around 4.1 billion euros corresponding to a risk-weighted exposure amount of approximately 1.3 billion euros, and deposit volumes of around 2.8 billion euros.

It also represents approximately 30 percent of the lending volumes and approximately 50 per cent of the risk-weighted exposure amounts in the Bank's operations in Finland.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Microsoft has launched a new category of Windows PCs designed for Artificial Intelligence (AI) that are slated to be the fastest and most intelligent Windows PCs ever built. The Copilot+ PCs come with built-in AI hardware and will support AI features across the operating system. Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit. While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings...

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
RELATED NEWS
Follow RTT